Literature DB >> 32449911

Performance of commercial methods for linezolid susceptibility testing of Enterococcus faecium and Enterococcus faecalis.

Loren Dejoies1,2, Sarrah Boukthir1, Gauthier Péan de Ponfilly3, Ronan Le Guen4, Asma Zouari1,5, Sophie Potrel1,5, Anaïs Collet1,5, Gabriel Auger1,5, Hervé Jacquier3, Vincent Fihman4,6, Laurent Dortet7, Vincent Cattoir1,2,5.   

Abstract

BACKGROUND: Linezolid-resistant enterococci (LRE) causing infections that are challenging to treat are rising, highlighting the need for reliable screening of LRE clinical isolates.
OBJECTIVES: To evaluate the ability of the broth microdilution (BMD) method for LRE detection and to assess the performance of seven commercially available techniques for linezolid susceptibility testing.
METHODS: A collection of 100 clinical isolates (80 Enterococcus faecium and 20 Enterococcus faecalis), including 20 optrA-positive isolates, 17 poxtA-positive isolates and 1 optrA/poxtA-positive E. faecium isolate, were studied. MICs were determined after 18 h [Day 1 (D1)] and 42 h [Day 2 (D2)] of incubation and interpreted following EUCAST and CLSI guidelines, which currently provide different interpretative breakpoints. Performance of commercial techniques was compared with BMD results.
RESULTS: MIC50/D1 and MIC50/D2 were both 8 mg/L, while MIC90/D1 and MIC90/D2 were 16 and 32 mg/L, respectively. MICD1 values for poxtA-positive isolates were lower than those for optrA-positive isolates. Proportions of susceptible isolates at D1 and D2 were 48% and 41%, respectively, according to EUCAST breakpoints and 35% and 13%, respectively, according to CLSI criteria (the proportions of isolates categorized as intermediate following CLSI recommendations were 13% and 28% at D1 and D2, respectively). Percentage susceptibility assessed by the commercially available techniques was always higher. The four commercial methods allowing MIC determination provided an overall essential agreement of ≥90% at D1. Categorical agreement and error rates were generally improved at D2.
CONCLUSIONS: Non-automated methods (Sensititre and UMIC) and, to a lesser extent, gradient strip Etest appear to show an acceptable correlation with the BMD reference method for the detection of isolates with low MICs of linezolid after prolonged incubation.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32449911     DOI: 10.1093/jac/dkaa180

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

Review 1.  Antimicrobial Susceptibility Testing for Enterococci.

Authors:  Ayesha Khan; William R Miller; Dierdre Axell-House; Jose M Munita; Cesar A Arias
Journal:  J Clin Microbiol       Date:  2022-06-13       Impact factor: 11.677

2.  Large diversity of linezolid-resistant isolates discovered in food-producing animals through linezolid selective monitoring in Belgium in 2019.

Authors:  Michaël Timmermans; Bert Bogaerts; Kevin Vanneste; Sigrid C J De Keersmaecker; Nancy H C Roosens; Carole Kowalewicz; Guillaume Simon; Maria A Argudín; Ariane Deplano; Marie Hallin; Pierre Wattiau; David Fretin; Olivier Denis; Cécile Boland
Journal:  J Antimicrob Chemother       Date:  2021-12-24       Impact factor: 5.790

3.  Mobile Oxazolidinone Resistance Genes in Gram-Positive and Gram-Negative Bacteria.

Authors:  Stefan Schwarz; Wanjiang Zhang; Xiang-Dang Du; Henrike Krüger; Andrea T Feßler; Shizhen Ma; Yao Zhu; Congming Wu; Jianzhong Shen; Yang Wang
Journal:  Clin Microbiol Rev       Date:  2021-06-02       Impact factor: 50.129

4.  Evaluation of CHROMagar™ LIN-R for the Screening of Linezolid Resistant Staphylococci from Positive Blood Cultures and Nasal Swab Screening Samples.

Authors:  Delphine Girlich; Liliana Mihaila; Vincent Cattoir; Frédéric Laurent; Christine Begasse; Florence David; Carole-Ann Metro; Laurent Dortet
Journal:  Antibiotics (Basel)       Date:  2022-02-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.